GLUcose Transport and REnalPROtection in Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a single-center, double blind, randomized, parallel-arms study designed to
investigate the effects of a six-month treatment with the SGLT2i dapagliflozin on markers of
kidney senescence, inflammation and tubulointerstitial damage compared to placebo. These
mechanisms of renal damage will be investigated in proximal tubular epithelial cells (PTECs)
isolated from urine from patients with CKD with or without T2DM and in renal biopsy specimens
in a subgroup of patients with diabetic kidney disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy